Crinetics Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 8 | -$1.29 | -$0.33 | -$0.81 |
| Q2 2024 | 8 | -$1.37 | -$0.35 | -$0.86 |
| Q3 2024 | 8 | -$1.45 | -$0.37 | -$0.91 |
| Q4 2024 | 10 | -$1.10 | -$0.76 | -$0.90 |
| Q1 2025 | 6 | -$1.20 | -$0.85 | -$0.96 |
| Q2 2025 | 5 | -$1.63 | -$0.41 | -$1.02 |
| Q3 2025 | 5 | -$1.76 | -$0.44 | -$1.10 |
| Q4 2025 | 5 | -$1.80 | -$0.46 | -$1.13 |
| Q1 2026 | 2 | -$1.68 | -$0.42 | -$1.05 |
| Q2 2026 | 2 | -$1.72 | -$0.44 | -$1.08 |
| Q3 2026 | 2 | -$1.76 | -$0.45 | -$1.11 |
| Q4 2026 | 2 | -$1.80 | -$0.46 | -$1.13 |
Crinetics Pharmaceuticals, Inc. Earnings Date And Information
Crinetics Pharmaceuticals, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-0.96 earnings per share for the quarter, missing analysts' consensus estimates of $-0.91 by $0.05. The company had revenue of 0 for the quarter and had revenue of 4.01 M for the year. Crinetics Pharmaceuticals, Inc. has generated $-4 earnings per share over the last year ($-3.69 diluted earnings per share) and currently has a price-to-earnings ratio of -16.16. Crinetics Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Crinetics Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.91 | -$0.96 | -0.05 | $218,091 | $0 |
| 08/08/2024 | Q2 2024 | -$0.86 | -$0.94 | -0.08 | $467,273 | $399,000 |
| 05/09/2024 | Q1 2024 | -$0.84 | -$0.93 | -0.09 | $640,000 | |
| 12/29/2023 | Q4 2023 | -$0.90 | $0 | |||
| 11/07/2023 | Q3 2023 | -$0.89 | -$1.01 | -0.12 | $346,000 | |
| 08/08/2023 | Q2 2023 | -$0.85 | -$0.94 | -0.09 | $1.10 M | $988,000 |
| 05/09/2023 | Q1 2023 | -$0.82 | $2.68 M | |||
| 02/28/2023 | Q4 2022 | -$0.82 | -$0.79 | 0.03 | $709,000 | |
| 11/14/2022 | Q3 2022 | -$0.78 | -$0.75 | 0.03 | $250,000 | $458,000 |
| 08/12/2022 | Q2 2022 | -$0.62 | -$0.79 | -0.17 | $600,000 | $439,000 |
| 05/12/2022 | Q1 2022 | -$0.56 | -$0.75 | -0.19 | $3.13 M | |
| 03/30/2022 | Q4 2021 | -$0.57 | -$0.68 | -0.11 | $1.08 M | |
| 11/05/2021 | Q3 2021 | -$0.70 | -$0.73 | -0.03 | $0 | |
| 08/10/2021 | Q2 2021 | -$0.60 | -$0.70 | -0.1 | $0 | |
| 05/06/2021 | Q1 2021 | -$0.65 | -$0.69 | -0.04 | $0 | |
| 03/30/2021 | Q4 2020 | -$0.58 | -$0.66 | -0.08 | $0 | |
| 11/06/2020 | Q3 2020 | -$0.52 | -$0.56 | -0.04 | $0 | |
| 08/07/2020 | Q2 2020 | -$0.52 | -$0.53 | -0.01 | $0 | |
| 05/08/2020 | Q1 2020 | -$0.63 | -$0.71 | -0.08 | $71,000 | |
| 03/09/2020 | Q4 2019 | -$0.67 | -$0.60 | 0.07 | $321,000 |
Crinetics Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Crinetics Pharmaceuticals, Inc.'s earnings date?
Crinetics Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
How can I listen to Crinetics Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Crinetics Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Crinetics Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Crinetics Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much revenue does Crinetics Pharmaceuticals, Inc. generate each year?
Crinetics Pharmaceuticals, Inc. (:CRNX) has a recorded annual revenue of $4.01 M.
-
How much profit does Crinetics Pharmaceuticals, Inc. generate each year?
Crinetics Pharmaceuticals, Inc. (:CRNX) has a recorded net income of $4.01 M. Crinetics Pharmaceuticals, Inc. has generated $-3.69 earnings per share over the last four quarters.
-
What is Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio?
Crinetics Pharmaceuticals, Inc. (:CRNX) has a price-to-earnings ratio of -16.16 and price/earnings-to-growth ratio is -12.22.
